Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

142.74 -1.75 (-1.21%)
Official Closing Price Updated: 7:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,757,547
Open 144.66
Bid (Size) 142.50 (1)
Ask (Size) 144.39 (1)
Prev. Close 144.49
Today's Range 142.67 - 145.59
52wk Range 75.56 - 148.15
Shares Outstanding N/A
Dividend Yield 1.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Wegovy was just approved in China. 
Via The Motley Fool

Performance

YTD
+39.79%
+39.79%
1 Month
+5.51%
+5.51%
3 Month
+11.91%
+11.91%
6 Month
+39.79%
+39.79%
1 Year
+79.06%
+79.06%

More News

Read More
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Via The Motley Fool
This Is Massive News for Eli Lilly Investors
Via The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
Via Chartmill
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
Via Investor's Business Daily
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Via Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
Via Benzinga
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Via Benzinga
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Via Benzinga
Topics Fraud Supply Chain
Exposures Legal Supply Chain
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Via Benzinga
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Via Benzinga
Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
Via InvestorPlace
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Via The Motley Fool
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
Via Benzinga
Why Novo Nordisk Shares Are Trading Higher Tuesday
Via Benzinga
Novo Nordisk Wins Approval For Its Weight-Loss Drug From China
Via Talk Markets
European Stocks Dip As US Market Sentiment Sours
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.